Ticker: MDGL

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is a biopharmaceutical company focused on addressing metabolic dysfunction-associated steatohepatitis (MASH) through its FDA-approved product, Rezdiffra. As of June 30, 2025, the company has faced both notable successes and challenges. Below is an ove...